policy and special-interest areas
In the Strategic Business Plan for 2009-2013 we
identify and discuss five strategic objectives. Our objectives
for the next five years are:
- Clear all assessment backlogs by 2011
- Continue to develop a scientifically robust, consistent and
transparent assessment system
- Assist and invest in efforts to strengthen the medicinal
product regulatory chain, both at national and European level
- Strengthen scientific underpinning
- Knowledge must be translated and disseminated.
In 2005, the MEB published a special-interest policy paper. This
paper adresses both basic disciplines as special-interest
(clinical) areas.
These clinical areas are:
- Psychiatry, dementia, epilepsy and cerebrovascular
disorders
- Vaccines
- Female hormones and other products that influence the function
of the urogenital system
- Cardiovascular disorders 1 and treatments for associated
metabolic risk factors (diabetes and obesity, including
lipid-lowering medicines)
- Oncology including haematological oncology